Study reveals low utilization of PCSK9 inhibitors in high-risk patients

A new study published in Circulation: Cardiovascular Quality and Outcomes from the Family Heart Foundation -; a patient-centered research and advocacy nonprofit organization dedicated to improving the lives of families impacted by inherited lipid disorders and LDL-cholesterol -; revealed that utilization of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) to reduce low-density lipoprotein cholesterol (LDL-C) remains low among high-risk patients.

BGI Genomics enhances NIFTY prenatal testing kit with DNBSEQ-G99 platform for faster and accurate results

BGI Europe A/S, a wholly owned subsidiary of BGI Genomics, announced its NIFTY non-invasive prenatal testing kit and software (CE-IVDD List B) were granted an

February 22, 2024

Opinion | ‘More and More Patients in Less and Less Time’: What We Heard This Week

“It feels like we’re being asked to see more and more patients in less and less time.” — Meghan Lelonek, MD, a hospitalist with Sound

June 3, 2024

Lilly exec says developing new therapies for lupus is ‘in scope’

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.